EDMONTON, ALBERTA--(Marketwired - Jan. 8, 2015) - Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for health care and cosmetic industries, announced today that its President and Chief Executive Officer, Gilles Gagnon M.Sc., MBA, will be presenting at the Eighth Annual OneMedForum being held January 12 - 13, 2015, at the Marriott Marquis in San Francisco, CA.
| Event: |
OneMedForum Presentation |
| Date: |
Tuesday, January 13, 2015 |
| Time: |
11:50 a.m. Pacific Time / 2:50 p.m. Eastern Time |
| Location: |
Marriott Marquis, San Francisco, CA |
Mr. Gagnon will provide a corporate overview and an update on the development programs for its two essential pharmaceutical grade active ingredients, avenanthramides and beta glucan. Ceapro is developing beta glucan and avenanthramides for expansion beyond cosmeceutials into the nutraceutical and pharmaceutical markets for potential use in anti-inflammatory therapies, anti-aging and wound healing treatments, and cholesterol management.
A live webcast of the corporate presentation will be available on the Company's website at www.ceapro.com. The webcast replay will be available approximately two hours after each presentation ends and will be accessible for one month.
About OneMedForum
OneMedForum was launched in 2008 to bring together the companies and investors that OneMedPlace was beginning to cultivate through its online community. The date and location were selected to leverage the influx of healthcare investors and company executives that gather each January in San Francisco. OneMed has continuously worked to facilitate the discovery of lesser-known quality companies, with a range of media tools, technologies, and content that have been developed over the past eight years. Since 2008, over 400 companies have presented at OneMedForum, and almost 300 leading investors have served on panels.
About Ceapro Inc.
Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and "active ingredients" from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company's website at www.ceapro.com.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.